0 0 0 -0.00424107142857138 -4.46428571428165E-05 0.00111607142857143 -0.00165178571428573 0.00109375000000002
Sign Up Today X
Thanks for submitting the form.
Stockreport

Vertex Expands Cystic Fibrosis Reach As Kidney Drug Nears FDA Decision [Yahoo! Finance]

Vertex Pharmaceuticals Incorporated (VRTX)  More Company Research Source: Yahoo! Finance
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
Vertex Pharmaceuticals received FDA approval for expanded use of its cystic fibrosis therapies, increasing the number of eligible patients. The company also completed a priority Biologics License Application submission to the FDA for povetacicept for IgA nephropathy. These regulatory milestones relate directly to areas of high unmet medical need in respiratory and kidney disease. Vertex Pharmaceuticals (NasdaqGS:VRTX) is drawing attention after securing broader FDA approvals for its cystic fibrosis portfolio and advancing povetacicept into priority review. The stock last closed at $446.54, with a 3 year return of 42.0% and a 5 year return of 107.4%. This provides context for how the market has previously reacted to the company's drug pipeline and commercial progress. For investors, an important consideration is how these regulatory steps may relate to patient uptake and revenue over time in cystic fibrosis and IgA nephropathy. The expanded cystic fibrosis eligibility and pote [Read more]
IMPACT SNAPSHOT EVENT TIME: VRTX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
VRTX alerts
from News Quantified
VRTX
NEWS
VRTX
Earnings
VRTX
Analyst Actions
VRTX
SEC Filings
Stockreport

Vertex Expands Cystic Fibrosis Reach As Kidney Drug Nears FDA Decision [Yahoo! Finance]

Vertex Pharmaceuticals Incorporated  (VRTX) 
More Company Research Source: Yahoo! Finance
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
Vertex Pharmaceuticals received FDA approval for expanded use of its cystic fibrosis therapies, increasing the number of eligible patients. The company also completed a priority Biologics License Application submission to the FDA for povetacicept for IgA nephropathy. These regulatory milestones relate directly to areas of high unmet medical need in respiratory and kidney disease. Vertex Pharmaceuticals (NasdaqGS:VRTX) is drawing attention after securing broader FDA approvals for its cystic fibrosis portfolio and advancing povetacicept into priority review. The stock last closed at $446.54, with a 3 year return of 42.0% and a 5 year return of 107.4%. This provides context for how the market has previously reacted to the company's drug pipeline and commercial progress. For investors, an important consideration is how these regulatory steps may relate to patient uptake and revenue over time in cystic fibrosis and IgA nephropathy. The expanded cystic fibrosis eligibility and pote [Read more]
IMPACT SNAPSHOT
EVENT TIME:
VRTX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS